Secondary analysis and integration of existing data to study cancer risk and outcomes (R21; no clinical trials)
This R21 opportunity funds innovative secondary analyses and integration of existing clinical, genomic, environmental, surveillance, and behavioral datasets to elucidate cancer risk, progression, survival, and treatment response. Projects must use existing data (no new primary data collection; up to 10% of budget allowed for limited validation), include plans for harmonization and broad data s…
Source
Award
Dates
Eligibility
Keywords
Supporting Links
Documents
Similar Opportunities
Get the full picture on this opportunity
Create a free Scout account to unlock everything you need to decide fast and win the grant.
-
Instant Fit Analysis
Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
-
Deep agency & funder detail
Program context, sub-agency structure, and a full eligibility breakdown.
-
Source links & full documents
Jump straight to the solicitation and download every attachment.
-
Similar opportunities
Discover related funding matched to your work.
Already have an account? Sign In
Trusted by 500+ Happy Customers